Navigation Links
Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
Date:9/18/2013

melanoma patients."

There are now 44 patients enrolled in the study with full enrollment forecast by the end of 2013.

Additional details about the Phase 2 CALM clinical trial can be found in the full ASX release issued by Viralytics:

http://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01444703

Full details of the clinical trial design can be found at the following website:

http://clinicaltrials.gov/show/NCT01227551

About Viralytics Ltd:

Viralytics is developing oncolytic virotherapy treatments for a range of cancers.  Viralytics' lead product, CAVATAK™, is a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21).  CVA21 binds to specific "receptor" proteins highly expressed on multiple cancer types including, but not limited to melanoma, prostate, lung, breast and bladder cancers; and multiple myeloma.  Intratumourally administered CAVATAKTM is currently being studied in a Phase 2 clinical trial in the treatment of Late stage Melanoma (the CALM study) at multiple cancer clinics in the US. 

Viralytics plans to commence a Phase I/II trial of CAVATAK™ being delivered systemically (intravenously). This trial referred to as the STORM (Systemic Treatment Of Resistant Malignancies) study will be undertaken in patients with melanoma, prostate, lung or metastatic bladder cancers. Viralytics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency and will commence the STORM trial at three prominent UK sites later in 2013.

Based in Sydney Australia, Viralytics is listed on the Australian Securities Exchange (ASX: VLA) while its ADRs also trade under VRACY on the US OTCQX International market.
'/>"/>

SOURCE Viralytics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
2. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
3. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
4. ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
5. TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
6. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
9. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
10. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
11. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... According to a new ... Devices Market (Embolic Protection, Chronic Total Occlusion, Atherectomy, ... Filters, Stents, Balloons and Accessories) - Forecasts to ... Peripheral Vascular Devices Market is expected to reach ... of 7.4% from 2014 to 2019. ...
(Date:6/3/2015)...  SurgiQuest®, Inc. ("SurgiQuest", the "Company"), a leading ... surgery (MIS) announced today that surgeons have successfully ... Adoption has risen rapidly with a 150% growth ... the company,s expansion from robotics into the general ... over 45 countries.   The AirSeal ...
(Date:6/3/2015)... , June 3, 2015 PillPack, the pharmacy ... a $50 million round of financing led by CRV ... and Sherpa Ventures. The capital will be used to ... and build retail pharmacies in US markets. ... a better, simpler pharmacy experience that folks absolutely love," ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Rapid Procedure Growth With SurgiQuest's AirSeal System 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... , MELBOURNE, Australia, Nov. 18 ... pleased to announce a successful capital raising of A$15.6 ... investors, taking the company,s cash reserves to approximately A$24 ... Orbis, an existing Starpharma shareholder and a highly regarded ...
... Nov. 18 Rules-Based Medicine, Inc. (RBM) today announced it ... Covance Inc. (NYSE: CVD ) that will provide ... technologies and services for use in drug development. Under terms ... third-party provider of multiplexed protein biomarker testing services, and RBM ...
Cached Medicine Technology:Starpharma Announces $15.6 million Capital Raising 2Starpharma Announces $15.6 million Capital Raising 3Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:6/3/2015)... 2015 Vancouver personal injury lawyers at ... will now handle personal injury claims resulting due to ... rise, more and more people turn towards mass transportation ... needless suffering, serious injury and also deaths. , ... bus accident in BC you may have an ICBC ...
(Date:6/3/2015)... June 03, 2015 Array Health ... technology, has announced that CEO Jonathan Rickert will present ... on June 4, 2015. The session will address ... are disrupting traditional business models in health care, and ... , WHAT: Digital Transformation and the Health Care ...
(Date:6/3/2015)... Washington, DC (PRWEB) June 03, 2015 ... Inc. will be honored with a Global Inspire Award ... program recognizes the organization’s outstanding volunteers for their leadership, ... global scale. , The recipients of the ... or group of authors whose article has made a ...
(Date:6/3/2015)... 03, 2015 Z-Medica®, LLC, a leading ... June has been designated as National Safety Month by ... AZ. Police Department for its commitment to public safety. ... their Individual First Aid Kits (IFAK) over 100 times ... shootings, stabbings or traffic accidents. Each kit is equipped ...
(Date:6/3/2015)... NC (PRWEB) June 03, 2015 Researchers ... two biomarkers for mesothelioma and say the tried-and-true marker ... just posted an article on the research. Click ... the University’s National Center for Asbestos Related Diseases say, ... positive results, it is still preferable to fibulin-3 for ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Z-Medica Commends Tucson Police Department for Trauma Kit Utilization 2Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2
... to turn back the clock on aging stem cells ... in a fracture every three seconds worldwide, according to ... the right signals could help aging stem cells act ... death and disability associated with a frail framework, Georgia ...
... WEDNESDAY, June 8 (HealthDay News) -- The U.S. Food and ... the popular statin Zocor because of an increased risk of ... This risk has been seen among some people taking 80 ... year of treatment, the agency said. In light of this, ...
... winter 2009-2010 was much more widespread than was previously realised, research ... year at the end of the H1N1 flu season showed that ... of the 44 per cent who tested positive had contracted swine ... flu, or had been vaccinated. The research, led by ...
... Randy Dotinga HealthDay Reporter , WEDNESDAY, June 8 (HealthDay ... may be available in the United States as soon as this ... for the scans to be of much help for those ... earlier diagnosis, which can be important to people who want to ...
... HealthDay Reporter , WEDNESDAY, June 8 (HealthDay News) -- Girls ... explain some cases of autism in families with no history ... a certain number of duplications or deletions of one or ... explained Dr. Christian Schaaf, an assistant professor in the department ...
... The University of Alabama at Birmingham has taken a ... patient care with its acquisition of the first cell-processing workstation ... States. Richard Marchase, Ph.D., vice president for Research ... history of breaking ground in the cell-therapy arena. We are ...
Cached Medicine News:Health News:Researchers work to turn back the clock on bone-producing stem cells 2Health News:Researchers work to turn back the clock on bone-producing stem cells 3Health News:Researchers work to turn back the clock on bone-producing stem cells 4Health News:FDA Places New Warning Label on Zocor 2Health News:FDA Places New Warning Label on Zocor 3Health News:Brain Scans to Spot Alzheimer's May Be Available This Year 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 2Health News:Girls May Be More Resistant to Autism Than Boys: Study 3Health News:Girls May Be More Resistant to Autism Than Boys: Study 4Health News:UAB first in US with cell-processing workstation 2Health News:UAB first in US with cell-processing workstation 3
... Flextend lead is a ... with an extendable/retractable active-fixation ... design offers various lead ... implantation in the atrium ...
... leads are implantable bipolar extendable/retractable screw-in ... either the atrium or the ventricle. ... be extended or retracted by turning ... contains an anti-chattering mechanism for steady ...
Used with permanent pacing leads....
... Tupos LA, the only ICD system in ... the first implant for the treatment of ... a lasting improvement of their hemodynamics and ... LA uses biatrial stimulation to effectively suppress ...
Medicine Products: